• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, August 27, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

New Texas Heart Institute study outlines additional reasons for optimism related to heart regeneration

Bioengineer by Bioengineer
September 15, 2021
in Biology
Reading Time: 4 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

The Texas Heart Institute has announced that a new study from its prolific Cardiomyocyte Renewal Lab has been published in Circulation Research – a peer-reviewed journal from the American Heart Association that reaches clinical and academic cardiologists, basic cardiovascular scientists, physiologists, cellular and molecular biologists, and cardiovascular pharmacologists. The new study identifies that the Wntless (Wls) gene plays a critical role in heart regeneration in mice. Wls facilitate signal molecule secretion from cardiomyocytes (heart muscle cells) to cardiac fibroblasts – cells that produce connective tissue – in order to suppress CF activation, which in turn promotes heart functional recovery by reducing scar formation.

New Texas Heart Institute Study Outlines Additional Reasons for Optimism Related to Heart Regeneration

Credit: © Texas Heart Institute
All Rights Reserved

The Texas Heart Institute has announced that a new study from its prolific Cardiomyocyte Renewal Lab has been published in Circulation Research – a peer-reviewed journal from the American Heart Association that reaches clinical and academic cardiologists, basic cardiovascular scientists, physiologists, cellular and molecular biologists, and cardiovascular pharmacologists. The new study identifies that the Wntless (Wls) gene plays a critical role in heart regeneration in mice. Wls facilitate signal molecule secretion from cardiomyocytes (heart muscle cells) to cardiac fibroblasts – cells that produce connective tissue – in order to suppress CF activation, which in turn promotes heart functional recovery by reducing scar formation.

“In this study, we learned that the Hippo pathway, an inhibitory genetic mechanism, regulates cardiac scar formation based upon cross-communication between cardiomyocytes and cardiac fibroblasts vis-à-vis the Wnt signaling pathway; based upon this discovery, we are able to reduce scarring that is formed by fibroblasts following a myocardial infarction (heart attack) in neonatal mouse hearts,” emphasized Shijie Liu, a Research Scientist in the Texas Heart Institute Cardiomyocyte Renewal Laboratory and a co-author on the study.

Liu has worked closely with Dr. James Martin, Director of the Cardiomyocyte Renewal Lab, on several studies, including a recently published study in Science Translational Medicine that represents a game-changing step forward for the treatment of heart failure using gene therapy to regenerate heart muscle following myocardial infarction. Liu previously spent time at the University of North Carolina working on oncology research before transitioning to cardiovascular investigation in 2016 under Martin’s tutelage at the Texas Heart Institute.

“Moving forward, we hope to build upon the animal model for heart regeneration that has been developed through this research and will continue to press forward on working to understand the cross-talk that happens between cardiomyocytes and cardiac fibroblasts, which is a complex realm of study that involves a number of different cell conversations occurring simultaneously,” Liu added. He concluded, “Further research could potentially lead to heart regeneration treatments that work in multiple ways instead of just one. We are optimistic about where this research is headed based upon this study in tandem with the paper we published a few months ago. The future is very bright, and I am excited to continue working with Dr. Martin and his team at the Texas Heart Institute.”

Texas Heart Institute’s Cardiomyocyte Renewal Laboratory focuses on understanding how genetic pathways are connected to adult tissue homeostasis and regeneration. By obtaining an in-depth understanding of these pathways, the team cultivates techniques to prevent disorders like heart failure and atrial fibrillation and develops new treatments to ameliorate heart disease. The newly published study, Yap Promotes Noncanonical Wnt Signals from Cardiomyocytes for Heart Regeneration, represents the latest in a number of research breakthroughs for the department.

Liu S, Tang L, Zhao X, Nguyen B, Heallen TR, Li M, Wang J, Wang J, Martin JF. Yap Promotes Noncanonical Wnt Signals from Cardiomyocytes for Heart Regeneration. Circ Res. 2021 Aug 23. doi: 10.1161/CIRCRESAHA.121.318966. Epub ahead of print. PMID: 34424032.

###

ABOUT TEXAS HEART INSTITUTE (THI)

The Texas Heart Institute, founded by world-renowned cardiovascular surgeon Dr. Denton A. Cooley in 1962, is a nonprofit organization dedicated to reducing the devastating toll of cardiovascular disease through innovative and progressive programs in research, education, and improved patient care. THI’s scientists and physicians conduct fundamental biomedical, translational, and clinical research in cardiology, cardiovascular surgery, molecular-based medicine, stem cell and gene therapy, and regenerative medicine both independently and in collaboration with organizations worldwide. As global leaders of patient care for nearly six decades, Texas Heart Institute has been ranked among the top cardiovascular centers in the United States by U.S. News & World Report for the past 30 years. THI is dedicated to spreading awareness and sharing updates on ways to prevent, treat and defeat cardiovascular disease. With over 10 million visitors coming to its website from around the world every year, www.texasheart.org is just one of the ways THI is helping to educate people on the importance of heart health. For more information, please visit https://www.texasheart.org.

ABOUT THE CARDIOMYOCYTE RENEWAL LAB AT THI

The Texas Heart Institute Cardiomyocyte Renewal Laboratory addresses major areas of disease-related research including heart failure and atrial fibrillation. Led by James Martin, MD, PhD, the lab’s groundbreaking studies have yielded exciting results, including discovering the genetic pathway that prevents the heart from regenerating after an injury. This key biological insight revealed that a failing organ, in this case the heart, can be rejuvenated by removing a specific, inhibitory genetic signal. The team is dedicated to continuing their work in basic research to develop new treatments for heart disease. This includes developing innovative gene therapies to treat severe heart disease such as heart failure. The lab will conduct further molecular analyses to define novel targets for cardiac regeneration therapy. Cutting-edge approaches, such as gene-editing technology, will be used to develop novel cardiac therapies. For more information, please visit https://www.texasheart.org/research/cardiomyocyte-renewal-laboratory/.



Journal

Circulation Research

DOI

10.1161/CIRCRESAHA.121.318966

Method of Research

Experimental study

Subject of Research

Animals

Article Title

Yap Promotes Noncanonical Wnt Signals from Cardiomyocytes for Heart Regeneration

Article Publication Date

23-Aug-2021

COI Statement

JFM is a co-founder of and owns shares in Yap Therapeutics.

Share12Tweet8Share2ShareShareShare2

Related Posts

blank

New Mitochondrial Genome Unveils Monodactylus sebae Insights

August 27, 2025
Identifying Genes Linked to Fat Traits in Xiang Pigs

Identifying Genes Linked to Fat Traits in Xiang Pigs

August 27, 2025

CircCOG5 Regulates Ferroptosis in Ovarian Cancer

August 27, 2025

Heat Stress Impact on Aged Hens’ Health and Performance

August 27, 2025

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    148 shares
    Share 59 Tweet 37
  • Molecules in Focus: Capturing the Timeless Dance of Particles

    142 shares
    Share 57 Tweet 36
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    115 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    81 shares
    Share 32 Tweet 20

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

OLED-Driven Metasurfaces Enable Holographic Projections

Understanding Female-to-Female Aggression in Workspaces

Thirst in Post-Surgery Children: A Cross-Sectional Study

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.